You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

SAPROPTERIN DIHYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sapropterin Dihydrochloride patents expire, and when can generic versions of Sapropterin Dihydrochloride launch?

Sapropterin Dihydrochloride is a drug marketed by Annora Pharma, Dr Reddys, and Par Pharm Inc. and is included in eight NDAs.

The generic ingredient in SAPROPTERIN DIHYDROCHLORIDE is sapropterin dihydrochloride. There are three drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sapropterin dihydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sapropterin Dihydrochloride

A generic version of SAPROPTERIN DIHYDROCHLORIDE was approved as sapropterin dihydrochloride by PAR PHARM INC on May 10th, 2019.

  Try a Trial

Drug patent expirations by year for SAPROPTERIN DIHYDROCHLORIDE
Drug Prices for SAPROPTERIN DIHYDROCHLORIDE

See drug prices for SAPROPTERIN DIHYDROCHLORIDE

Recent Clinical Trials for SAPROPTERIN DIHYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
West China HospitalPhase 1
University of PittsburghPhase 1/Phase 2
Ira FoxPhase 1/Phase 2

See all SAPROPTERIN DIHYDROCHLORIDE clinical trials

Paragraph IV (Patent) Challenges for SAPROPTERIN DIHYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KUVAN Powder for Oral Solution sapropterin dihydrochloride 500 mg per packet 205065 1 2017-02-23
KUVAN Powder for Oral Solution sapropterin dihydrochloride 100 mg per packet 205065 1 2015-11-09
KUVAN Tablets sapropterin dihydrochloride 100 mg 022181 1 2014-06-05

US Patents and Regulatory Information for SAPROPTERIN DIHYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Annora Pharma SAPROPTERIN DIHYDROCHLORIDE sapropterin dihydrochloride POWDER;ORAL 215420-001 Aug 18, 2022 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Annora Pharma SAPROPTERIN DIHYDROCHLORIDE sapropterin dihydrochloride TABLET;ORAL 215534-001 Aug 23, 2022 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys SAPROPTERIN DIHYDROCHLORIDE sapropterin dihydrochloride POWDER;ORAL 215798-001 May 13, 2022 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys SAPROPTERIN DIHYDROCHLORIDE sapropterin dihydrochloride TABLET;ORAL 207685-001 Jun 15, 2021 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.